#Asset-Light Business Model
Explore articles tagged with Asset-Light Business Model
A New Chapter in Europe
HRV Pharma has entered the European finished formulations market through its acquisition of Germany-based Phatebo. The move gives HRV an established pharmaceutical business with wholesale authorisation, good distribution practice systems and an existing customer base, complementing its global API portfolio.
Two Bets on Complex Molecules, One Asset Light Model
HRV Pharma is planning a ₹150 crore investment in peptides and high-potency APIs through a dedicated peptide programme and a joint venture focused on specialised oncology molecules. Both initiatives follow the company's asset-light model, retaining intellectual property, regulatory assets and commercial rights while working with specialist manufacturing partners.
No Factory, ₹400 Crore Revenue: How HRV Made It Happen
How does HRV Pharma generate over ₹400 crore in revenue without owning a manufacturing plant? Discover its asset-light business model, network of 50+ US FDA and EU approved manufacturing partners, and growth to 700+ customers across 55 countries.